Could High-Dose vitamin D3 shield pregnant women from preeclampsia?
NCT ID NCT07648706
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two different doses of vitamin D3 supplements in pregnant women who have low vitamin D levels. The goal is to see if a higher dose (50,000 IU every two weeks) is better than a lower dose (5,000 IU weekly) at preventing preeclampsia, a serious pregnancy complication involving high blood pressure. The trial enrolls women with a single baby, between 8 and 18 weeks of pregnancy, and follows them through delivery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Vitamin D3
What this could lead to
If successful, this could show that higher vitamin D3 doses during pregnancy reduce the risk of preeclampsia, a dangerous condition for both mother and baby.
What could go wrong
This is a relatively small, single-hospital study, so results may not apply to all populations. The optimal dose and safety of high-dose vitamin D3 in pregnancy are still being explored.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREECLAMPSIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Faculty of Medicine and Health Sciences, Sana'a University
RECRUITINGSanaa, Maeen District, Yemen
Contact Phone: •••-•••-•••• Email: •••••@•••••